CANY
INFI

Caxton Associates (New York)’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Caxton Associates (New York)’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,046
Closed -$45K – 757
2021
Q4 		$45K Buy
+20,046
New +$50.3K ﹤0.01% 540

Other funds holding INFI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Caxton Associates (New York)'s INFI Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2022, closing a stake of 20,046 shares — an estimated $45K sold.

Caxton Associates (New York) first reported a position in INFI in Q4 2021 and held it in 1 quarter. The position peaked at $45K in Q4 2021. 93 funds tracked by Wall St. Rank hold INFI as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 20,046 Infinity Pharmaceuticals, Inc. shares in Q1 2022, an estimated $45K.
  • Caxton Associates (New York) first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Infinity Pharmaceuticals, Inc. position peaked at $45K in Q4 2021.
  • 93 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.